Co-diagnostics Newsroom

H.C. Wainwright Maintains Co-diagnostics(CODX.US) With Hold Rating, Maintains Target Price $1.5

Futu NewsNov 11 20:31

Cautious Outlook: Co-Diagnostics Hold Rating Amid Revenue Decline and Regulatory Uncertainties

TipRanksNov 11 19:51

Co-Diagnostics Analyst Ratings

BenzingaNov 11 19:46

HC Wainwright & Co. Reiterates Neutral on Co-Diagnostics, Maintains $1.5 Price Target

BenzingaNov 11 19:46

Co-Diagnostics Analyst Ratings

BenzingaAug 13 02:20

Hold Rating Maintained for Co-Diagnostics Amidst Revenue Growth and Development Progress

TipRanksAug 12 21:57

HC Wainwright & Co. Reiterates Neutral on Co-Diagnostics, Maintains $2 Price Target

BenzingaJun 17 22:57

Co-Diagnostics Analyst Ratings

BenzingaJun 17 22:56

HC Wainwright & Co. : Maintain the Co-Diagnostics (CODX.US) rating, adjust from neutral to neutral, and adjust the target price from $2.50 to $2.00.

Zhitong FinanceMay 13 19:10

Co-Diagnostics Analyst Ratings

BenzingaMay 13 19:10

HC Wainwright & Co. Maintains Neutral on Co-Diagnostics, Lowers Price Target to $2

BenzingaMay 13 19:10

Co-Diagnostics Analyst Ratings

BenzingaMar 15 18:50

HC Wainwright & Co. Maintains Neutral on Co-Diagnostics, Lowers Price Target to $2.5

BenzingaMar 15 18:50

HC Wainwright & Co. Reiterates Neutral on Co-Diagnostics, Maintains $3 Price Target

BenzingaDec 29, 2023 19:34

Co-Diagnostics Analyst Ratings

BenzingaDec 29, 2023 19:32

Analysts' Opinions Are Mixed on These Healthcare Stocks: Natera (NTRA) and Co-Diagnostics (CODX)

TipRanksDec 29, 2023 19:20

HC Wainwright & Co. Maintains Neutral on Co-Diagnostics, Raises Price Target to $3

BenzingaNov 13, 2023 23:43

Co-Diagnostics Analyst Ratings

BenzingaNov 13, 2023 23:33

Hold Rating on Co-Diagnostics: Revenue Decline Offset by Grant, FDA Submission on the Horizon, and Strong Cash Position Amid Potential Risks

TipRanksNov 13, 2023 19:40

HC Wainwright & Co. Maintains Neutral on Co-Diagnostics, Lowers Price Target to $2

BenzingaAug 14, 2023 18:46